INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 3 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,432 | +96.4% | 20 | +42.9% | 0.00% | – |
| Q3 2023 | $729 | -49.9% | 14 | -39.1% | 0.00% | – |
| Q2 2023 | $1,456 | +92.1% | 23 | +64.3% | 0.00% | – |
| Q1 2023 | $758 | +2.3% | 14 | 0.0% | 0.00% | – |
| Q4 2022 | $741 | -25.9% | 14 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 14 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | – | 14 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 14 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 14 | – | 0.00% | – |
| Q2 2017 | $0 | – | 0 | -100.0% | 0.00% | – |
| Q1 2017 | $0 | – | 19 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |